Research programme: thymalfasin analogues - SciClone
Latest Information Update: 27 Mar 2009
At a glance
- Originator SciClone Pharmaceuticals
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Hepatitis B; Hepatitis C
Most Recent Events
- 02 Apr 2003 No development reported - Preclinical for Cancer in USA (unspecified route)
- 02 Apr 2003 No development reported - Preclinical for Hepatitis B in USA (unspecified route)
- 02 Apr 2003 No development reported - Preclinical for Hepatitis C in USA (unspecified route)